APA (7th ed.) Citation

TB, J., JJ, B., S, L., MA, P., KA, W., JT, C., . . . JM, W. (2023). Early postnatal administration of an AAV9 gene therapy is safe and efficacious in CLN3 disease. Frontiers in genetics, 14, 1118649. https://doi.org/10.3389/fgene.2023.1118649

Chicago Style (17th ed.) Citation

TB, Johnson, et al. "Early Postnatal Administration of an AAV9 Gene Therapy Is Safe and Efficacious in CLN3 Disease." Frontiers in Genetics 14 (2023): 1118649. https://doi.org/10.3389/fgene.2023.1118649.

MLA (9th ed.) Citation

TB, Johnson, et al. "Early Postnatal Administration of an AAV9 Gene Therapy Is Safe and Efficacious in CLN3 Disease." Frontiers in Genetics, vol. 14, 2023, p. 1118649, https://doi.org/10.3389/fgene.2023.1118649.